MSD to Acquire Harpoon Therapeutics for USD 680 Million, Expanding Its Oncology Pipeline
Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has announced its...
Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has announced its...